Cangene, Akzo Nobel Pharma deal

CNJ completed the previously announced sale of its nucleic acid sequencing based amplification (NASBA) technology to Akzo for C$22 million (US$16.5 million) (see BioCentury Sep. 25). The bulk of the p...